Iris Unimi Prodmetadata only
The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries
myelofibrosi, overall survival, ruxolitinib, starting dose, settore meds-09/b - malattie del sangue
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 185485
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.